

Palovarotene: Adis Evaluation

Key Points

- A selective retinoic acid receptor (RAR) γ agonist is being developed by Ipsen for the reduction of heterotopic ossification (HO) formation in patients with fibrodysplasia ossificans progressiva (FOP)
- Received its first approval on 21 January 2022 in Canada
- Approved to reduce the formation of HO in adults and children aged 8 years and above for females and 10 years and above for males with FOP

Summary

Palovarotene (Sohonos™) is an orally bioavailable selective RAR γ agonist being developed by Ipsen for the reduction of HO formation in patients with FOP.

By binding to RAR γ , palovarotene inhibits bone morphogenetic protein and SMAD 1/5/8 signalling: interfering with these pathways prevents chondrogenesis and ultimately HO by permitting normal muscle tissue repair or regeneration to occur.

Palovarotene received its first approval on 21 January 2022 to reduce the formation of HO in adults and children aged 8 years and above for females and 10 years and above for males with FOP in Canada.

This summary represents the opinions of the [author/authors]. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.